GlobeNewswire Inc.··NaINmune Bio to Unveil Q1 2026 Results Amid Clinical-Stage Immunology Development
$INMB will report Q1 2026 financials May 7th, providing updates on its three immunology product platforms targeting inflammation and innate immune disorders.
INMBconference callclinical-stage biotechnology